Structure Therapeutics Initiates Phase 2a Study of Oral GLP-1 agonist GSBR-1290 for…
<!-- Name:DistributionId Value:8846943 -->
<!-- Name:EnableQuoteCarouselOnPnr Value:False -->…
Quick News Bit